Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 13c ; Provides outlook

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of ($1.02), $0.13 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.07 million versus the consensus estimate of $7.53 million.

Outlook:-

GAAP operating expense range: $ 580 to $ 610

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• SpaceX short interest at 5-7% of float - S3 Partners
• Craig-Hallum Upgrades Backblaze Inc (BLZE) to Buy